Safety and Adverse Events Related to Inactivated COVID-19 Vaccines and Novavax; a Systematic Review
Archives of Academic Emergency Medicine,
Vol. 10 No. 1 (2022),
1 Dey 2022
,
Page e54
https://doi.org/10.22037/aaem.v10i1.1585
Abstract
Introduction: Knowledge of the safety of vaccines is crucial, both to prevent and cure them and to decrease the public hesitation in receiving vaccines. Therefore, this study aimed to systematically review the adverse events reported for inactivated vaccines and Novavax.
Methods: In this systematic review, the databases of PubMed, Scopus, Cochrane, and Web of Science were searched on September 15, 2021. Then we identified the eligible studies using a two-step title/abstract and full-text screening process. Data on the subjects, studies, and types of adverse events were extracted and entered in a word table, including serious, mild, local, and systemic adverse events as well as the timing of side effects’ appearance.
Results: Adverse effects of inactivated coronavirus vaccines side effects were reported from phases 1, 2, and 3 of the vaccine trials. The most common local side effects included injection site pain and swelling, redness, and pruritus. Meanwhile, fatigue, headache, muscle pain, fever, and gastrointestinal symptoms including abdominal pain and diarrhea were among the most common systemic adverse effects.
Conclusion: This systematic review indicates that inactivated COVID-19 vaccines, including Sinovac, Sinopharm, and Bharat Biotech, as well as the protein subunit vaccines (Novavax) can be considered as safe choices due to having milder side effects and fewer severe life-threatening adverse events.
- Adverse Effects
- BBV152 COVID-19 vaccine
- COVID-19
- COVID-19 vaccines
- recombinant SARS-CoV-2 vaccine NVX-cov2373
- Safety
- SARS-CoV-2
- sinovac COVID-19 vaccine
- Vaccines, Inactivated
How to Cite
References
Petrosillo N, Viceconte G, Ergonul O, Ippolito G, Petersen E. COVID-19, SARS and MERS: are they closely related? Clinical microbiology and infection. 2020;26(6):729-34.
Dadras O, Alinaghi SAS, Karimi A, MohsseniPour M, Barzegary A, Vahedi F, et al. Effects of COVID-19 prevention procedures on other common infections: a systematic review. European journal of medical research. 2021;26(1):67.
Qin C, Liu F, Yen T-C, Lan X. 18F-FDG PET/CT findings of COVID-19: a series of four highly suspected cases. European journal of nuclear medicine and molecular imaging. 2020;47(5):1281-6.
Sanie Jahromi MS, Aghaei K, Taheri L, Kalani N, Hatami N, Rahmanian Z. Intensive Care Unit of COVID-19 during the Different Waves of Outbreaks in Jahrom, South of Iran. Journal of Medicinal and Chemical Sciences. 2022;5(5):734-42.
Sheikhbahaei E, Mirghaderi SP, Moharrami A, Habibi D, Motififard M, Mortazavi SMJ. Incidence of Symptomatic COVID-19 in Unvaccinated Patients Within One Month After Elective Total Joint Arthroplasty: A Multicenter Study. Arthroplast Today. 2022;14:110-5.
Wilder-Smith A, Freedman DO. Isolation, quarantine, social distancing and community containment: pivotal role for old-style public health measures in the novel coronavirus (2019-nCoV) outbreak. Journal of travel medicine. 2020.
Vellozzi C, Burwen DR, Dobardzic A, Ball R, Walton K, Haber P. Safety of trivalent inactivated influenza vaccines in adults: background for pandemic influenza vaccine safety monitoring. Vaccine. 2009;27(15):2114-20.
Gao Q, Bao L, Mao H, Wang L, Xu K, Yang M, et al. Development of an inactivated vaccine candidate for SARS-CoV-2. Science. 2020;369(6499):77-81.
Wang Z-J, Zhang H-J, Lu J, Xu K-W, Peng C, Guo J, et al. Low toxicity and high immunogenicity of an inactivated vaccine candidate against COVID-19 in different animal models. Emerging microbes & infections. 2020;9(1):2606-18.
Wang H, Zhang Y, Huang B, Deng W, Quan Y, Wang W, et al. Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2. Cell. 2020;182(3):713-21. e9.
Wu Z, Hu Y, Xu M, Chen Z, Yang W, Jiang Z, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. The Lancet Infectious Diseases. 2021;21(6):803-12.
Ella R, Vadrevu KM, Jogdand H, Prasad S, Reddy S, Sarangi V, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial. The Lancet Infectious Diseases. 2021;21(5):637-46.
Zhao J, Zhao S, Ou J, Zhang J, Lan W, Guan W, et al. COVID-19: coronavirus vaccine development updates. Frontiers in immunology. 2020;11:3435.
Xia S, Duan K, Zhang Y, Zhao D, Zhang H, Xie Z, et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. Jama. 2020;324(10):951-60.
Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. The Lancet Infectious Diseases. 2021;21(1):39-51.
Sudharsanan N, Favaretti C, Hachaturyan V, Bärnighausen T, Vandormael A. The effect of framing and communicating COVID-19 vaccine side-effect risks on vaccine intentions for adults in the UK and the USA: A structured summary of a study protocol for a randomized controlled trial. Trials. 2021;22(1):592.
Hoffman Y, Palgi Y, Goodwin R, Ben-Ezra M, Greenblatt-Kimron L. A storm in a teacup: older adults' low prevalence of COVID-19 vaccine side-effects and their link with vaccination anxiety. International psychogeriatrics. 2021;33(12):1335-7.
Keech C, Albert G, Cho I, Robertson A, Reed P, Neal S, et al. Phase 1–2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. New England Journal of Medicine. 2020;383(24):2320-32.
Yang S, Li Y, Dai L, Wang J, He P, Li C, et al. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. The Lancet Infectious Diseases. 2021;21(8):1107-19.
Meira CM, Jr., Meneguelli KS, Leopoldo MPG, Florindo AA. Anxiety and Leisure-Domain Physical Activity Frequency, Duration, and Intensity During Covid-19 Pandemic. Frontiers in psychology. 2020;11:603770.
(WHO) WHO. 10 Vaccines Approved for Use by WHO 2021 [updated 27 December 2021; cited 2021 28 December]. Available from: https://covid19.trackvaccines.org/agency/who/.
Panda DS, Giri RK, Nagarajappa AK, Basha S. Covid-19 vaccine, acceptance, and concern of safety from public perspective in the state of Odisha, India. Human vaccines & immunotherapeutics. 2021;17(10):3333-7.
Joffe S, Babiker A, Ellenberg SS, Fix A, Griffin MR, Hunsberger S, et al. Data and Safety Monitoring of COVID-19 Vaccine Clinical Trials. The Journal of infectious diseases. 2021;224(12):1995-2000.
Riad A, Schünemann H, Attia S, Peričić TP, Žuljević MF, Jürisson M, et al. COVID-19 Vaccines Safety Tracking (CoVaST): Protocol of a Multi-Center Prospective Cohort Study for Active Surveillance of COVID-19 Vaccines' Side Effects. International journal of environmental research and public health. 2021;18(15):7859.
Li X, Ostropolets A, Makadia R, Shoaibi A, Rao G, Sena AG, et al. Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study. BMJ (Clinical research ed). 2021;373:n1435.
Karayeva E, Kim HW, Bandy U, Clyne A, Marak TP. Monitoring Vaccine Adverse Event Reporting System (VAERS) Reports Related to COVID-19 Vaccination Efforts in Rhode Island. Rhode Island medical journal (2013). 2021;104(7):64-6.
Guo W, Duan K, Zhang Y, Yuan Z, Zhang YB, Wang Z, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18 years or older: A randomized, double-blind, placebo-controlled, phase 1/2 trial. EClinicalMedicine. 2021;38:101010.
Al Khames Aga QA, Alkhaffaf WH, Hatem TH, Nassir KF, Batineh Y, Dahham AT, et al. Safety of COVID-19 vaccines. Journal of medical virology. 2021;93(12):6588-94.
Abu-Hammad O, Alduraidi H, Abu-Hammad S, Alnazzawi A, Babkair H, Abu-Hammad A, et al. Side Effects Reported by Jordanian Healthcare Workers Who Received COVID-19 Vaccines. Vaccines. 2021;9(6):577.
Xia S, Duan K, Zhang Y, Zhao D, Zhang H, Xie Z, et al. Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials. Jama. 2020;324(10):951-60.
Niebel D, Novak N, Wilhelmi J, Ziob J, Wilsmann-Theis D, Bieber T, et al. Cutaneous Adverse Reactions to COVID-19 Vaccines: Insights from an Immuno-Dermatological Perspective. Vaccines. 2021;9(9):944.
Abu-Halaweh S, Alqassieh R, Suleiman A, Al-Sabbagh MQ, AbuHalaweh M, AlKhader D, et al. Qualitative Assessment of Early Adverse Effects of Pfizer-BioNTech and Sinopharm COVID-19 Vaccines by Telephone Interviews. Vaccines. 2021;9(9):950.
Kaur RJ, Dutta S, Bhardwaj P, Charan J, Dhingra S, Mitra P, et al. Adverse Events Reported From COVID-19 Vaccine Trials: A Systematic Review. Indian J Clin Biochem. 2021;36(4):427-39.
Hatmal MM, Al-Hatamleh MAI, Olaimat AN, Hatmal M, Alhaj-Qasem DM, Olaimat TM, et al. Side Effects and Perceptions Following COVID-19 Vaccination in Jordan: A Randomized, Cross-Sectional Study Implementing Machine Learning for Predicting Severity of Side Effects. Vaccines. 2021;9(6):556.
Wang G, Zhu L, Zhu Y, Ye Q, Yu X, Fu M, et al. Safety survey by clinical pharmacists on COVID-19 vaccination from a single center in China. Human vaccines & immunotherapeutics. 2021;17(9):2863-7.
Pu J, Yu Q, Yin Z, Zhang Y, Li X, Yin Q, et al. The safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in Chinese adults aged 18-59 years: A phase I randomized, double-blinded, controlled trial. Vaccine. 2021;39(20):2746-54.
Pichi F, Aljneibi S, Neri P, Hay S, Dackiw C, Ghazi NG. Association of Ocular Adverse Events With Inactivated COVID-19 Vaccination in Patients in Abu Dhabi. JAMA ophthalmology. 2021;139(10):1131-5.
Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. The Lancet Infectious diseases. 2021;21(1):39-51.
Fan YJ, Chan KH, Hung IF. Safety and Efficacy of COVID-19 Vaccines: A Systematic Review and Meta-Analysis of Different Vaccines at Phase 3. Vaccines. 2021;9(9):989.
Saeed BQ, Al-Shahrabi R, Alhaj SS, Alkokhardi ZM, Adrees AO. Side effects and perceptions following Sinopharm COVID-19 vaccination. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2021;111:219-26.
Tanriover MD, Doğanay HL, Akova M, Güner HR, Azap A, Akhan S, et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet (London, England). 2021;398(10296):213-22.
SeyedAlinaghi S, Mirzapour P, Dadras O, Pashaei Z, Karimi A, MohsseniPour M, et al. Characterization of SARS-CoV-2 different variants and related morbidity and mortality: a systematic review. European journal of medical research. 2021;26(1):51.
Zhang MX, Zhang TT, Shi GF, Cheng FM, Zheng YM, Tung TH, et al. Safety of an inactivated SARS-CoV-2 vaccine among healthcare workers in China. Expert review of vaccines. 2021;20(7):891-8.
Yang ZN, Zhao YY, Li L, Gao HD, Cai Q, Sun XX, et al. [Evaluation of safety of two inactivated COVID-19 vaccines in a large-scale emergency use]. Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi. 2021;42:1-6.
Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. The Lancet Infectious diseases. 2021;21(2):181-92.
Kaya F, Pirincci E. Determining the frequency of serious adverse reactions of inactive SARS-COV-2 vaccine. Work (Reading, Mass). 2021;69(3):735-9.
Wu Z, Hu Y, Xu M, Chen Z, Yang W, Jiang Z, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. The Lancet Infectious diseases. 2021;21(6):803-12.
Ella R, Reddy S, Jogdand H, Sarangi V, Ganneru B, Prasad S, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial. The Lancet Infectious diseases. 2021;21(7):950-61.
Goepfert PA, Fu B, Chabanon AL, Bonaparte MI, Davis MG, Essink BJ, et al. Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1-2, dose-ranging study. The Lancet Infectious diseases. 2021;21(9):1257-70.
Heath PT, Galiza EP, Baxter DN, Boffito M, Browne D, Burns F, et al. Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine. The New England journal of medicine. 2021;385(13):1172-83.
Han B, Song Y, Li C, Yang W, Ma Q, Jiang Z, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial. The Lancet Infectious diseases. 2021;21(12):1645-53.
- Abstract Viewed: 1138 times
- pdf Downloaded: 165 times